79 results on '"Muñoz-Calleja C"'
Search Results
2. Combined Dendritic Cell And Anti-TIGIT Immunotherapy Potentiate Trail+ Memory NK Cells Against HIV-1 Infected Cells
- Author
-
Sánchez-Cerrillo, I, primary, Popova, O, additional, Agudo-Lera, M, additional, Tsukalov, I, additional, Calvet-Mirabent, M, additional, de los Santos, I, additional, García-Fraile, L, additional, Fuentes, P, additional, Delgado-Arévalo, C, additional, Alcain, J, additional, Sánchez-Gaona, N, additional, Lázaro-Díez, M, additional, Muñoz-Calleja, C, additional, Alfranca, Arantzazu, additional, Genescà, M, additional, Prado, JG, additional, Vbrnac, Vladimir, additional, Balazs, Alejandro, additional, Buzón, MJ, additional, Toribio, M.L, additional, Muñoz-Fernández, MA, additional, Sánchez-Madrid, F, additional, and Martín-Gayo, E, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Cigarette smoke induces pulmonary arterial dysfunction through an imbalance in the redox status of the soluble guanylyl cyclase
- Author
-
Sevilla-Montero, J., primary, Munar-Rubert, O., additional, Pino-Fadón, J., additional, Aguilar-Latorre, C., additional, Villegas-Esguevillas, M., additional, Climent, B., additional, Agrò, M., additional, Choya-Foces, C., additional, Martínez-Ruiz, A., additional, Balsa, E., additional, Muñoz-Calleja, C., additional, Gómez-Punter, R.M., additional, Vázquez-Espinosa, E., additional, Cogolludo, A., additional, and Calzada, M.J., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication
- Author
-
Arteche-López, A, Kreutzman, A, Alegre, A, Sanz Martín, P, Aguado, B, González-Pardo, M, Espiño, M, Villar, L M, García Belmonte, D, de la Cámara, R, and Muñoz-Calleja, C
- Published
- 2017
- Full Text
- View/download PDF
5. A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD
- Author
-
Portero-Sainz, I, Gómez-García de Soria, V, Cuesta-Mateos, C, Fernández-Arandojo, C, Vega-Piris, L, Royg, M, Colom-Fernández, B, Marcos-Jiménez, A, Somovilla-Crespo, B, Ramírez-Mengíbar, A, López-Huete, V, de Rosendo-Serrano, A, Kreutzman, A, and Muñoz-Calleja, C
- Published
- 2017
- Full Text
- View/download PDF
6. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility
- Author
-
Cuesta-Mateos, C., Colom-Fernández, B., Portero-Sainz, I., Tejedor, R., García-García, C., Concha-Garzón, M. J., De las Heras-Alonso, M. E., Martínez, M. A., Juarez, C., and Muñoz-Calleja, C.
- Published
- 2015
- Full Text
- View/download PDF
7. Development of an Autoimmune Syndrome Affecting the Skin and Internal Organs in P-Selectin Glycoprotein Ligand 1 Leukocyte Receptor–Deficient Mice
- Author
-
Pérez-Frías, A., González-Tajuelo, R., Núñez-Andrade, N., Tejedor, R., García-Blanco, M. J., Vicente-Rabaneda, E., Castañeda, S., Gamallo, C., Silván, J., Esteban-Villafruela, A., Cubero-Rueda, L., García-García, C., Muñoz-Calleja, C., García-Diez, A., and Urzainqui, A.
- Published
- 2014
- Full Text
- View/download PDF
8. S897 VALIDATION OF A NOVEL MECHANISM OF ACTION FOR TREATMENT OF CCR7+ HEMATOLOGICAL MALIGNANCIES WITH FIRST-IN-CLASS ANTIBODY CAP-100
- Author
-
Cuesta-Mateos, C., primary, Juarez-Sánchez, R., additional, Mateu-Albero, T., additional, Muñoz-Calleja, C., additional, Loscertales, J., additional, Terrón, F., additional, and Wim, M., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients
- Author
-
Espiño, M, primary, Arteche-López, A, additional, Medina, S, additional, Muñoz-Calleja, C, additional, Blanchard, M J, additional, Alegre, A, additional, López-Jiménez, F J, additional, and Villar, L M, additional
- Published
- 2017
- Full Text
- View/download PDF
10. AB0033 B Cell Depletion by Rituximab in Lymphocyte Subpopupulations from Peripheral Blood in Patients with Rheumatoid Arthritis
- Author
-
Merino Meléndez, L., primary, Lόpez Lόpez, J., additional, Llorente, I., additional, Castañeda Sanz, S., additional, Herrera, F., additional, Velasco, T., additional, Alvaro-Gracia, J., additional, García-Vicuña, R., additional, Muñoz-Calleja, C., additional, and González-Άlvaro, I., additional
- Published
- 2015
- Full Text
- View/download PDF
11. 39 Phytochemical indole-3-carbinol synergizes strongly with fludarabine and induces p53-dependent and -independent cell death in chronic lymphocytic leukemia cells irrespective of their IGHV mutation state and treatment resistances
- Author
-
Perez-Chacon, G., primary, Martinez-Laperche, C., additional, Rebolleda, N., additional, Somovilla-Crespo, B., additional, Muñoz-Calleja, C., additional, Buño, I., additional, and Zapata, J.M., additional
- Published
- 2014
- Full Text
- View/download PDF
12. Serum Interleukin-8 Reflects Tumor Burden and Treatment Response Across Malignancies of Multiple Tissue Origins
- Author
-
Gracia, J.L. Perez, primary, Sanmamed, M.F., additional, Rua, O.E. Carranza, additional, Alfaro, C., additional, Oñate, C., additional, Martin-Algarra, S., additional, Perez, G., additional, Landázuri, S.F., additional, Gonzalez, A., additional, Gross, S., additional, Lopez, I. Rodriguez, additional, Muñoz-Calleja, C., additional, RodrÍguez-Ruiz, M.E., additional, Sangro, B., additional, Lopez-Picazo, J.M., additional, Rizzo, M., additional, Mazzolini, G., additional, and Melero, I., additional
- Published
- 2014
- Full Text
- View/download PDF
13. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility
- Author
-
Cuesta-Mateos, C., primary, Colom-Fernández, B., additional, Portero-Sainz, I., additional, Tejedor, R., additional, García-García, C., additional, Concha-Garzón, M.J., additional, De las Heras-Alonso, M.E., additional, Martínez, M.A., additional, Juarez, C., additional, and Muñoz-Calleja, C., additional
- Published
- 2014
- Full Text
- View/download PDF
14. AB0227 PSGL-1 deficiency develops systemic sclerosis in mice
- Author
-
Urzainqui, A., primary, Perez-Frias, A., additional, Gonzalez-Tajuelo, R., additional, Nuñez-Andrade, N., additional, Tejedor, R., additional, Muñoz-Calleja, C., additional, Castañeda, S., additional, Vicente, E., additional, Gamallo, C., additional, Fraga, J., additional, and García-Diez, A., additional
- Published
- 2013
- Full Text
- View/download PDF
15. 252P - Serum Interleukin-8 Reflects Tumor Burden and Treatment Response Across Malignancies of Multiple Tissue Origins
- Author
-
Gracia, J.L. Perez, Sanmamed, M.F., Rua, O.E. Carranza, Alfaro, C., Oñate, C., Martin-Algarra, S., Perez, G., Landázuri, S.F., Gonzalez, A., Gross, S., Lopez, I. Rodriguez, Muñoz-Calleja, C., RodrÍguez-Ruiz, M.E., Sangro, B., Lopez-Picazo, J.M., Rizzo, M., Mazzolini, G., and Melero, I.
- Published
- 2014
- Full Text
- View/download PDF
16. Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables.
- Author
-
Delgado-Wicke P, Fernández de Córdoba-Oñate S, Roy-Vallejo E, Alegría-Carrasco E, Rodríguez-Serrano DA, Lamana A, Montes N, Nicolao-Gómez A, Carracedo-Rodríguez R, Marcos-Jiménez A, Díaz-Fernández P, Galván-Román JM, Rabes-Rodríguez L, Sanz-Alba M, Álvarez-Rodríguez J, Villa-Martí A, Rodríguez-Franco C, Villapalos-García G, Zubiaur P, Abad-Santos F, de Los Santos I, Gomariz RP, García-Vicuña R, Muñoz-Calleja C, González-Álvaro I, and Fernández-Ruiz E
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Toll-Like Receptor 7 genetics, TYK2 Kinase genetics, Genotype, Genetic Predisposition to Disease, 2',5'-Oligoadenylate Synthetase genetics, COVID-19 genetics, COVID-19 immunology, COVID-19 virology, Polymorphism, Single Nucleotide, Severity of Illness Index, SARS-CoV-2 genetics, SARS-CoV-2 immunology
- Abstract
The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02-0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56-0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5-0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07-1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97-1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95-1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation.
- Author
-
Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh KA, Powell K, Ji H, Hernandez GM, Abelin J, Klaeger S, Forman C, Clauser KR, Sarkizova S, Braun DA, Penter L, Kim HT, Lane WJ, Oliveira G, Kean LS, Li S, Livak KJ, Carr SA, Keskin DB, Muñoz-Calleja C, Ho VT, Ritz J, Soiffer RJ, Neuberg D, Stewart C, Getz G, and Wu CJ
- Abstract
T cell alloreactivity against minor histocompatibility antigens (mHAgs)-polymorphic peptides resulting from donor-recipient (D-R) disparity at sites of genetic polymorphisms-is at the core of the therapeutic effect of allogeneic hematopoietic cell transplantation (allo-HCT). Despite the crucial role of mHAgs in graft-versus-leukemia (GvL) and graft-versus-host disease (GvHD) reactions, it remains challenging to consistently link patient-specific mHAg repertoires to clinical outcomes. Here we devise an analytic framework to systematically identify mHAgs, including their detection on HLA class I ligandomes and functional verification of their immunogenicity. The method relies on the integration of polymorphism detection by whole-exome sequencing of germline DNA from D-R pairs with organ-specific transcriptional- and proteome-level expression. Application of this pipeline to 220 HLA-matched allo-HCT D-R pairs demonstrated that total and organ-specific mHAg load could independently predict the occurrence of acute GvHD and chronic pulmonary GvHD, respectively, and defined promising GvL targets, confirmed in a validation cohort of 58 D-R pairs, for the prevention or treatment of post-transplant disease recurrence., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
18. Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis.
- Author
-
H-Alcántara A, Kourani O, Marcos-Jiménez A, Martínez-Núñez P, Herranz-Martín E, Fuentes P, Toribio ML, Muñoz-Calleja C, Iglesias T, and Campanero MR
- Subjects
- Animals, Humans, Female, Mice, Male, Cell Line, Tumor, Cell Survival drug effects, Cell Proliferation drug effects, Carcinogenesis pathology, Carcinogenesis drug effects, Carcinogenesis metabolism, Lymphoma pathology, Lymphoma metabolism, Lymphoma drug therapy, Glutathione metabolism, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Neoplastic Stem Cells drug effects, Reactive Oxygen Species metabolism
- Abstract
Lymphoid tumor patients often exhibit resistance to standard therapies or experience relapse post-remission. Relapse is driven by Tumor Initiating Cells (TICs), a subset of tumor cells capable of regrowing the tumor and highly resistant to therapy. Growing cells in 3D gels is a method to discern tumorigenic cells because it strongly correlates with tumorigenicity. The finding that TICs, rather than differentiated tumor cells, grow in 3D gels offers a unique opportunity to unveil TIC-specific signaling pathways and therapeutic targets common to various cancer types. Here, we show that culturing lymphoid cells in 3D gels triggers reactive oxygen species (ROS) production, leading to non-tumor lymphoid cell death while enabling the survival and proliferation of a subset of lymphoma/leukemia cells, TICs or TIC-like cells. Treatment with the antioxidant N-acetylcysteine inhibits this lethality and promotes the growth of primary non-tumor lymphoid cells in 3D gels. A subset of lymphoma cells, characterized by an increased abundance of the antioxidant glutathione, escape ROS-induced lethality, a response not seen in non-tumor cells. Reducing glutathione production in lymphoma cells, either through pharmacological inhibition of glutamate cysteine ligase (GCL), the enzyme catalyzing the rate-limiting step in glutathione biosynthesis, or via knockdown of GCLC, the GCL catalytic subunit, sharply decreased cell growth in 3D gels and xenografts. Tumor cells from B-cell lymphoma/leukemia patients and λ-MYC mice, a B-cell lymphoma mouse model, overproduce glutathione. Importantly, pharmacological GCL inhibition hindered lymphoma growth in female λ-MYC mice, suggesting that this treatment holds promise as a therapeutic strategy for female lymphoma/leukemia patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study.
- Author
-
San Antonio E, Silván J, Sevilla-Montero J, González-Sánchez E, Muñoz-Callejas A, Sánchez-Abad I, Ramos-Manzano A, Muñoz-Calleja C, González-Álvaro I, Tomero EG, García-Pérez J, García-Vicuña R, Vicente-Rabaneda EF, Castañeda S, and Urzainqui A
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Aged, Scleroderma, Systemic blood, Scleroderma, Systemic diagnosis, Scleroderma, Systemic immunology, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic immunology, Biomarkers blood, ADAM Proteins blood, Membrane Glycoproteins blood, Membrane Proteins blood
- Abstract
Background: Early diagnosis and treatment of Systemic lupus erythematosus (SLE) and Systemic sclerosis (SSc) present significant challenges for clinicians. Although various studies have observed changes in serum levels of selectins between healthy donors and patients with autoimmune diseases, including SLE and SSc, their potential as biomarkers has not been thoroughly explored. We aimed to investigate serum profiles of PSGL-1 (sPSGL-1), ADAM8 (sADAM8) and P-, E- and L-selectins (sP-, sE- and sL-selectins) in defined SLE and SSc patient cohorts to identify disease-associated molecular patterns., Methods: We collected blood samples from 64 SLE patients, 58 SSc patients, and 81 healthy donors (HD). Levels of sPSGL-1, sADAM8 and selectins were analyzed by ELISA and leukocyte membrane expression of L-selectin and ADAM8 by flow cytometry., Results: Compared to HD, SLE and SSc patients exhibited elevated sE-selectin and reduced sL-selectin levels. Additionally, SLE patients exhibited elevated sPSGL-1 and sADAM8 levels. Compared to SSc, SLE patients had decreased sL-selectin and increased sADAM8 levels. Furthermore, L-selectin membrane expression was lower in SLE and SSc leukocytes than in HD leukocytes, and ADAM8 membrane expression was lower in SLE neutrophils compared to SSc neutrophils. These alterations associated with some clinical characteristics of each disease. Using logistic regression analysis, the sL-selectin/sADAM8 ratio in SLE, and a combination of sL-selectin/sE-selectin and sE-selectin/sPSGL-1 ratios in SSc were identified and cross-validated as potential serum markers to discriminate these patients from HD. Compared to available diagnostic biomarkers for each disease, both sL-selectin/sADAM8 ratio for SLE and combined ratios for SSc provided higher sensitivity (98% SLE and and 67% SSc correctly classified patients). Importantly, the sADAM8/% ADAM8(+) neutrophils ratio discriminated between SSc and SLE patients with the same sensitivity and specificity than current disease-specific biomarkers., Conclusion: SLE and SSc present specific profiles of sPSGL-1, sE-, sL-selectins, sADAM8 and neutrophil membrane expression which are potentially relevant to their pathogenesis and might aid in their early diagnosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 San Antonio, Silván, Sevilla-Montero, González-Sánchez, Muñoz-Callejas, Sánchez-Abad, Ramos-Manzano, Muñoz-Calleja, González-Álvaro, Tomero, García-Pérez, García-Vicuña, Vicente-Rabaneda, Castañeda and Urzainqui.)
- Published
- 2024
- Full Text
- View/download PDF
20. NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins.
- Author
-
Tsukalov I, Sánchez-Cerrillo I, Rajas O, Avalos E, Iturricastillo G, Esparcia L, Buzón MJ, Genescà M, Scagnetti C, Popova O, Martin-Cófreces N, Calvet-Mirabent M, Marcos-Jimenez A, Martínez-Fleta P, Delgado-Arévalo C, de Los Santos I, Muñoz-Calleja C, Calzada MJ, González Álvaro I, Palacios-Calvo J, Alfranca A, Ancochea J, Sánchez-Madrid F, and Martin-Gayo E
- Subjects
- Humans, Calcium-Binding Proteins metabolism, CARD Signaling Adaptor Proteins metabolism, Monocytes metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Nucleoproteins metabolism, SARS-CoV-2 metabolism, COVID-19 pathology, Inflammasomes metabolism
- Abstract
Increased recruitment of transitional and non-classical monocytes in the lung during SARS-CoV-2 infection is associated with COVID-19 severity. However, whether specific innate sensors mediate the activation or differentiation of monocytes in response to different SARS-CoV-2 proteins remain poorly characterized. Here, we show that SARS-CoV-2 Spike 1 but not nucleoprotein induce differentiation of monocytes into transitional or non-classical subsets from both peripheral blood and COVID-19 bronchoalveolar lavage samples in a NFκB-dependent manner, but this process does not require inflammasome activation. However, NLRP3 and NLRC4 differentially regulated CD86 expression in monocytes in response to Spike 1 and Nucleoprotein, respectively. Moreover, monocytes exposed to Spike 1 induce significantly higher proportions of Th1 and Th17 CD4 + T cells. In contrast, monocytes exposed to Nucleoprotein reduce the degranulation of CD8 + T cells from severe COVID-19 patients. Our study provides insights in the differential impact of innate sensors in regulating monocytes in response to different SARS-CoV-2 proteins, which might be useful to better understand COVID-19 immunopathology and identify therapeutic targets., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
- Author
-
Mateu-Albero T, Marcos-Jimenez A, Delgado-Wicke P, Terrón F, Loscertales J, López-Matencio JMS, Muñoz-Calleja C, and Cuesta-Mateos C
- Subjects
- Humans, Receptors, CCR7 therapeutic use, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use
- Abstract
The Bruton's tyrosine kinase inhibitor ibrutinib and the B-cell lymphoma 2 anti-apoptotic protein inhibitor venetoclax provide high response rates in chronic lymphocytic leukemia (CLL). However, there is a growing number of patients that relapse after treatment or show refractory disease, thus new targets and agents are still needed. We have previously reported the chemokine receptor CCR7 as a relevant deregulated target in CLL and have developed CAP-100, a novel therapeutic anti-CCR7 antibody that is under evaluation for relapse/refractory CLL (NCT04704323). While CCR7 expression has been shown to be down-modulated in CLL patients treated with ibrutinib, whether venetoclax acts in a similar manner remains unaddressed. Here, we aimed to document the impact of venetoclax on CCR7 expression in CLL cells, as well as on the pre-clinical activity of CAP-100. To this end, we addressed CCR7 expression by flow cytometry and the antibody efficacy by means of in vitro chemotactic and antibody-dependent cell-mediated cytotoxicity (ADCC) assays. Our data indicate that venetoclax treatment did not significantly modify CCR7 expression pattern nor CAP-100 mechanisms of action. Together, these findings support CAP-100 as an adjuvant therapy to venetoclax that may introduce additional modes of action in CLL therapy., (© 2023 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
22. Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis.
- Author
-
Roy-Vallejo E, Fernández De Córdoba-Oñate S, Delgado-Wicke P, Triguero-Martínez A, Montes N, Carracedo-Rodríguez R, Zurita-Cruz N, Marcos-Jiménez A, Lamana A, Galván-Román JM, Villapalos García G, Zubiaur P, Ciudad M, Rabes L, Sanz M, Rodríguez C, Villa A, Rodríguez JÁ, Marcos C, Hernando J, Díaz-Fernández P, Abad F, de Los Santos I, Rodríguez Serrano DA, García-Vicuña R, Suárez Fernández C, P Gomariz R, Muñoz-Calleja C, Fernández-Ruiz E, González-Álvaro I, Cardeñoso L, Barrios A, Sanz J, Casado P, Gutiérrez Á, Bautista A, Hernández P, Ruiz Giménez N, Moyano B, Gil P, Jesús Delgado M, Parra P, Sánchez B, Sáez C, Fernández Rico M, Arévalo Román C, Castañeda S, Llorente I, G Tomero E, García Castañeda N, Uriarte M, Fontán García-Rodrigo L, Domingo García D, Alarcón Cavero T, Auxiliadora Semiglia Chong M, Gutiérrez Cobos A, Sánchez-Madrid F, Martín Gayo E, Sánchez-Cerrillo I, Martínez-Fleta P, López-Sanz C, Gabrie L, Del Campo Guerola L, Tejedor R, Ancochea J, García Castillo E, Ávalos E, Sánchez-Azofra A, Alonso T, Cisneros C, Valenzuela C, Javier García Pérez F, María Girón R, Aspa J, Marcos C, Del Perpetuo Socorro Churruca M, Zamora E, Martínez A, Barrio Mayo M, Henares Espi R, Méndez R, Arribas D, Chicot Llano M, González B, Quicios B, Patiño P, Trigueros M, Dominguez Peña C, Jiménez Jiménez D, Villamayor P, Canabal A, de la Cámara R, Ortiz J, and Iturrate I
- Abstract
Introduction: SARS-CoV-2 viral load has been related to COVID-19 severity. The main aim of this study was to evaluate the relationship between SARS-CoV-2 viremia and SNPs in genes previously studied by our group as predictors of COVID-19 severity., Materials and Methods: Retrospective observational study including 340 patients hospitalized for COVID-19 in the University Hospital La Princesa between March 2020 and December 2021, with at least one viremia determination. Positive viremia was considered when viral load was above the quantifiable threshold (20 copies/ml). A total of 38 SNPs were genotyped. To study their association with viremia a multivariate logistic regression was performed., Results: The mean age of the studied population was 64.5 years (SD 16.6), 60.9% patients were male and 79.4% white non-Hispanic. Only 126 patients (37.1%) had at least one positive viremia. After adjustment by confounders, the presence of the minor alleles of rs2071746 ( HMOX1 ; T/T genotype OR 9.9 p < 0.0001), rs78958998 (probably associated with SERPING1 expression; A/T genotype OR 2.3, p = 0.04 and T/T genotype OR 12.9, p < 0.0001), and rs713400 (eQTL for TMPRSS2 ; C/T + T/T genotype OR 1.86, p = 0.10) were associated with higher risk of viremia, whereas the minor alleles of rs11052877 ( CD69 ; A/G genotype OR 0.5, p = 0.04 and G/G genotype OR 0.3, p = 0.01), rs2660 ( OAS1 ; A/G genotype OR 0.6, p = 0.08), rs896 ( VIPR1 ; T/T genotype OR 0.4, p = 0.02) and rs33980500 ( TRAF3IP2 ; C/T + T/T genotype OR 0.3, p = 0.01) were associated with lower risk of viremia., Conclusion: Genetic variants in HMOX1 (rs2071746), SERPING1 (rs78958998), TMPRSS2 (rs713400), CD69 (rs11052877), TRAF3IP2 (rs33980500), OAS1 (rs2660) and VIPR1 (rs896) could explain heterogeneity in SARS-CoV-2 viremia in our population., Competing Interests: FA, has been consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. IG-Á reports grants from Instituto de Salud Carlos III, during the course of the study; personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non-financial support from Roche Laboratories; research support from Gebro Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Roy-Vallejo, Fernández de Córdoba-Oñate, Delgado-Wicke, Triguero-Martínez, Montes, Carracedo-Rodríguez, Zurita-Cruz, Marcos-Jiménez, Lamana, Galván-Román, Villapalos García, Zubiaur, Ciudad, Rabes, Sanz, Rodríguez, Villa, Rodríguez, Marcos, Hernando, Díaz-Fernández, Abad, de los Santos, Rodríguez Serrano, García-Vicuña, Suárez Fernández, P. Gomariz, Muñoz-Calleja, Fernández-Ruiz, González-Álvaro Cardeñoso and the PREDINMUN-COVID Group.)
- Published
- 2023
- Full Text
- View/download PDF
23. Dasatinib-induced spleen contraction leads to transient lymphocytosis.
- Author
-
Marcos-Jiménez A, Carvoeiro DC, Ruef N, Cuesta-Mateos C, Roy-Vallejo E, Gómez-García de Soria V, Laganá C, Del Campo L, Zubiaur P, Villapalos-García G, Abad-Santos F, Stein JV, and Muñoz-Calleja C
- Subjects
- Humans, Dasatinib adverse effects, Spleen pathology, Pyrimidines adverse effects, Thiazoles adverse effects, Lymphocytosis chemically induced, Lymphocytosis pathology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology
- Abstract
The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome-positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib uptake. To date, the underlying physiological process linking dasatinib to lymphocytosis remains unknown. Here, we used a small rodent model to examine the mechanism of dasatinib-induced lymphocytosis, focusing on lymphocyte trafficking into and out of secondary lymphoid organs. Our data indicate that lymphocyte homing to lymph nodes and spleen remained unaffected by dasatinib treatment. In contrast, dasatinib promoted lymphocyte egress from spleen with kinetics consistent with the observed lymphocytosis. Unexpectedly, dasatinib-induced lymphocyte egress occurred independently of canonical sphingosine-1-phosphate-mediated egress signals; instead, dasatinib treatment led to a decrease in spleen size, concomitant with increased splenic stromal cell contractility, as measured by myosin light chain phosphorylation. Accordingly, dasatinib-induced lymphocytosis was partially reversed by pharmacological inhibition of the contraction-promoting factor Rho-rho associated kinase. Finally, we uncovered a decrease in spleen size in patients with CML who showed lymphocytosis immediately after dasatinib treatment, and this reduction was proportional to the magnitude of lymphocytosis and dasatinib plasma levels. In summary, our work provides evidence that dasatinib-induced lymphocytosis is a consequence of drug-induced contractility of splenic stromal cells., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy.
- Author
-
López-Nevado M, Ortiz-Martín J, Serrano C, Pérez-Saez MA, López-Lorenzo JL, Gil-Etayo FJ, Rodríguez-Frías E, Cabrera-Marante O, Morales-Pérez P, Rodríguez-Pinilla MS, Manso R, Salgado-Sánchez RN, Cerdá-Montagud A, Quesada-Espinosa JF, Gómez-Rodríguez MJ, Paz-Artal E, Muñoz-Calleja C, Arranz-Sáez R, and Allende LM
- Subjects
- Male, Humans, Germ-Line Mutation, Mutation genetics, Phenotype, Vitamin B 12, DNA-Binding Proteins genetics, Autoimmune Lymphoproliferative Syndrome diagnosis, Autoimmune Lymphoproliferative Syndrome genetics, Hematologic Neoplasms diagnosis, Hematologic Neoplasms genetics, Dioxygenases genetics
- Abstract
Somatic mutations in the ten-eleven translocation methylcytosine dioxygenase 2 gene (TET2) have been associated to hematologic malignancies. More recently, biallelic, and monoallelic germline mutations conferring susceptibility to lymphoid and myeloid cancer have been described. We report two unrelated autoimmune lymphoproliferative syndrome-like patients who presented with T-cell lymphoma associated with novel germline biallelic or monoallelic mutations in the TET2 gene. Both patients presented a history of chronic lymphoproliferation with lymphadenopathies and splenomegaly, cytopenias, and immune dysregulation. We identified the first compound heterozygous patient for TET2 mutations (P1) and the first ALPS-like patient with a monoallelic TET2 mutation (P2). P1 had the most severe form of autosomal recessive disease due to TET2 loss of function resulting in absent TET2 expression and profound increase in DNA methylation. Additionally, the immunophenotype showed some alterations in innate and adaptive immune system as inverted myeloid/plasmacytoid dendritic cells ratio, elevated terminally differentiated effector memory CD8 + T-cells re-expressing CD45RA, regulatory T-cells, and Th2 circulating follicular T-cells. Double-negative T-cells, vitamin B12, and IL-10 were elevated according to the ALPS-like suspicion. Interestingly, the healthy P1's brother carried a TET2 mutation and presented some markers of immune dysregulation. P2 showed elevated vitamin B12, hypergammaglobulinemia, and decreased HDL levels. Therefore, novel molecular defects in TET2 confirm and expand both clinical and immunological phenotype, contributing to a better knowledge of the bridge between cancer and immunity., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
25. Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation.
- Author
-
Bouthelier A, Fernández-Arroyo L, Mesa-Ciller C, Cibrian D, Martín-Cófreces NB, Castillo-González R, Calero M, Herráez-Aguilar D, Guajardo-Grence A, Pacheco AM, Marcos-Jiménez A, Quiroga B, Morado M, Monroy F, Muñoz-Calleja C, Sánchez-Madrid F, Urrutia AA, and Aragonés J
- Abstract
Inhibition of the heterodimeric amino acid carrier SLC7A5/SLC3A2 (LAT1/CD98) has been widely studied in tumor biology but its role in physiological conditions remains largely unknown. Here we show that the SLC7A5/SLC3A2 heterodimer is constitutively present at different stages of erythroid differentiation but absent in mature erythrocytes. Administration of erythropoietin (EPO) further induces SLC7A5/SLC3A2 expression in circulating reticulocytes, as it also occurs in anemic conditions. Although Slc7a5 gene inactivation in the erythrocyte lineage does not compromise the total number of circulating red blood cells (RBCs), their size and hemoglobin content are significantly reduced accompanied by a diminished erythroblast mTORC1 activity. Furthermore circulating Slc7a5 -deficient reticulocytes are characterized by lower transferrin receptor (CD71) expression as well as mitochondrial activity, suggesting a premature transition to mature RBCs. These data reveal that SLC7A5/SLC3A2 ensures adequate maturation of reticulocytes as well as the proper size and hemoglobin content of circulating RBCs., Competing Interests: The authors declare no competing interests., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
26. Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: Prospective cohort study and validation cohort.
- Author
-
Cardeñoso Domingo L, Roy Vallejo E, Zurita Cruz ND, Chicot Llano M, Ávalos Pérez-Urria E, Barrios A, Hernando Santos J, Ortiz J, Rodríguez García SC, Martín Ramírez A, Ciudad Sañudo M, Marcos C, García Castillo E, Fontán García-Rodrigo L, González B, Méndez R, Iturrate I, Sanz García A, Villa A, Sánchez Azofra A, Quicios B, Arribas D, Álvarez Rodríguez J, Patiño P, Trigueros M, Uriarte M, Triguero Martínez A, Arévalo C, Galván Román JM, García-Vicuña R, Ancochea J, Soriano JB, Canabal A, Muñoz Calleja C, De la Cámara R, Suarez Fernández C, González Álvaro I, and Rodríguez-Serrano DA
- Subjects
- Adult, Hospitalization, Humans, Prospective Studies, Retrospective Studies, SARS-CoV-2, Viremia, COVID-19 diagnosis
- Abstract
Early kinetics of SARS-CoV-2 viral load (VL) in plasma determined by quantitative reverse-transcription polymerase chain reaction (RT-PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single-center study including consecutive adult patients hospitalized with COVID-19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT-PCR was performed to assess SARS-CoV-2 VL. The main outcomes were in-hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID-19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU-admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1-15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3-28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8-22]; p < 0.0001). Relevant SARS-CoV-2 viremia in the first week of hospitalization was associated with higher in-hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort., (© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
27. Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9 + tumors.
- Author
-
Santamaria S, Delgado M, Botas M, Castellano E, Corraliza-Gorjon I, Lafuente P, Muñoz-Calleja C, Toribio ML, Kremer L, and Garcia-Sanz JA
- Subjects
- Animals, Heterografts, Humans, Mice, Receptors, CCR metabolism, Adenocarcinoma, Pancreatic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Abstract
Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of mice carrying human CCR9
+ T-ALL cell lines or primary T cell leukemias inhibits tumor growth and increases survival. The therapeutic effects of 92R are specific and synergize with chemotherapeutic agents increasing survival. Furthermore, 92R decreases size of non-hematopoietic tumors with a forced CCR9 expression and of solid tumors generated by the pancreatic adenocarcinoma cell line AsPC-1. In addition, a humanized version of 92R mAb (Srb1) is also able to inhibit growth of CCR9+ T-ALL tumor cells in vivo , increasing survival 2.66-fold. Finally, 92R mAb prevents liver accumulation of infiltrates and reduces tumor cell numbers in already formed infiltrates. Thus, the humanized version of 92R mAb (Srb1), displays therapeutic potential for CCR9+ tumor treatment and might represent one of the first therapeutic antibodies for precision medicine on T-ALL patients., Competing Interests: 92R mAb was generated by the lab of LK and developed by the labs of LK and JG-S and has been protected by the CSIC (US Patent 10,401,363; EP13382469.8); an additional patent application has been filed by the CSIC and SunRock Biopharma, Ltd. on the use of 92R in Srb1 in combination therapies for cancer (EP21382020.2). SunRock Biopharma, Ltd. (Santiago de Compostela, Spain) kindly provided the Srb1 antibody used for these experiments. Neither the financing bodies, the CSIC or SunRock Biopharma Ltd., had a role on the design of the study, data collection and analysis, nor in the decision to publish the manuscript. Therefore, the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Santamaria, Delgado, Botas, Castellano, Corraliza-Gorjon, Lafuente, Muñoz-Calleja, Toribio, Kremer and Garcia-Sanz.)- Published
- 2022
- Full Text
- View/download PDF
28. SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort.
- Author
-
Roy-Vallejo E, Cardeñoso L, Triguero-Martínez A, Chicot Llano M, Zurita N, Ávalos E, Barrios A, Hernando J, Ortiz J, Rodríguez-García SC, Ciudad Sañudo M, Marcos C, García Castillo E, Fontán García-Rodrigo L, González B, Méndez R, Iturrate I, Sanz-García A, Villa A, Sánchez-Azofra A, Quicios B, Arribas D, Álvarez Rodríguez J, Patiño P, Trigueros M, Uriarte M, Martín-Ramírez A, Arévalo Román C, Galván-Román JM, García-Vicuña R, Ancochea J, Muñoz-Calleja C, Fernández-Ruiz E, de la Cámara R, Suárez Fernández C, González-Álvaro I, and Rodríguez-Serrano DA
- Abstract
Background: Interleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort., Methods: Secondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command twoway of Stata., Results: A total of 57 patients were recruited, with median age of 63 years (IQR [53-81]), 61.4% male and 68.4% Caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with > 1.3 log10 copies/ml) and also in those with at least one IL6 > 30 pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age., Conclusion: In those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Roy-Vallejo, Cardeñoso, Triguero-Martínez, Chicot Llano, Zurita, Ávalos, Barrios, Hernando, Ortiz, Rodríguez-García, Ciudad Sañudo, Marcos, García Castillo, Fontán García-Rodrigo, González, Méndez, Iturrate, Sanz-García, Villa, Sánchez-Azofra, Quicios, Arribas, Álvarez Rodríguez, Patiño, Trigueros, Uriarte, Martín-Ramírez, Arévalo Román, Galván-Román, García-Vicuña, Ancochea, Muñoz-Calleja, Fernández-Ruiz, de la Cámara, Suárez Fernández, González-Álvaro, Rodríguez-Serrano and the PREDINMUN-COVID Group.)
- Published
- 2022
- Full Text
- View/download PDF
29. Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.
- Author
-
Mateu-Albero T, Marcos-Jimenez A, Wissmann S, Loscertales J, Terrón F, Stein JV, Muñoz-Calleja C, and Cuesta-Mateos C
- Abstract
Bruton's tyrosine kinase inhibitor ibrutinib has significantly changed treatment landscape in chronic lymphocytic leukemia (CLL). Growing evidence supports ibrutinib to work beyond the effect on tumor cells by means of, for example, restoring functionality of the T-cell compartment and increasing circulating T-cell numbers. Recent evidence suggests T-cell enhanced expansion, rather than increased egress from secondary lymphoid organs (SLO), as a root cause for ibrutinib-induced lymphocytosis. However, whether the latter physiological change is also a consequence of a forced retention in blood remains undisclosed. Since CCR7 is the main chemokine receptor taking over the homing of T-cells from peripheral compartments to lymph nodes and other SLO, we aimed to investigate the impact of ibrutinib on CCR7 functionality in T-cells. To this end, we documented receptor expression in T-cells from a large cohort of ibrutinib-treated CLL patients, and performed different in vivo and in vitro migration models. Overall, our data confirm that CCR7 expression or receptor-mediated migration in CLL T-cells is not affected by ibrutinib. Furthermore, it does not modulate CCR7-driven homing nor nodal interstitial migration. Together, our results support that ibrutinib-induced CLL T-cell accumulation in the blood stream is not derived from an impairment of CCR7-driven recirculation between the SLO and bloodstream, and therefore T-cell expansion is the most plausible cause.
- Published
- 2022
- Full Text
- View/download PDF
30. Monitoring and safety of CAR-T therapy in clinical practice.
- Author
-
Serra López-Matencio JM, Gómez Garcia de Soria V, Gómez M, Alañón-Plaza E, Muñoz-Calleja C, and Castañeda S
- Subjects
- Cytokine Release Syndrome etiology, Cytokine Release Syndrome prevention & control, Humans, Immunotherapy, Adoptive adverse effects, Neoplasms etiology, Neurotoxicity Syndromes etiology, Receptors, Chimeric Antigen
- Abstract
Introduction: In the last few years, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells, has been developed. CAR-T cells are highly effective at inhibiting antitumor activity, but they can cause a wide spectrum of unusual side effects., Areas Covered: The present review provides an overview of the adverse events of CAR-T cell therapy, focusing on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, increased risk of infections, and other long-term complications. Representative studies addressing the safety and efficacy of CAR-T cell therapy are summarized., Expert Opinion: In the coming years, we predict a great expansion in the use of CAR-T cell therapy with it applied to a higher number of patients with both malignant neoplasms and immune-mediated diseases. Despite physicians and patient expectations about the potential of this therapy, there are still several barriers that may limit providers' ability to supply quality care. This exciting and powerful new therapy requires the formation of new multidisciplinary teams to carry out a safe treatment administration and to successfully manage the resultant complications. The follow-up of these therapies is important for two aspects: effectiveness in different populations and real-life safety in short and in long-term follow-up.
- Published
- 2022
- Full Text
- View/download PDF
31. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
- Author
-
Mateu-Albero T, Juárez-Sánchez R, Loscertales J, Mol W, Terrón F, Muñoz-Calleja C, and Cuesta-Mateos C
- Subjects
- Adenine pharmacology, Antibody-Dependent Cell Cytotoxicity drug effects, Antibody-Dependent Cell Cytotoxicity immunology, Cell Line, Tumor, Dose-Response Relationship, Drug, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Membrane Proteins genetics, Membrane Proteins metabolism, Receptors, CCR7 antagonists & inhibitors, Receptors, CCR7 metabolism, Adenine analogs & derivatives, Antineoplastic Agents, Immunological pharmacology, Gene Expression Regulation, Neoplastic drug effects, Piperidines pharmacology, Protein Kinase Inhibitors pharmacology, Receptors, CCR7 genetics
- Abstract
CAP-100 is a novel therapeutic antibody directed against the ligand binding site of human CCR7. This chemokine receptor is overexpressed in chronic lymphocytic leukemia (CLL) and orchestrates the homing of CLL cells into the lymph node. Previous studies, on a very limited number of samples, hypothesized that the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib might induce loss of surface CCR7 levels in CLL cells. CAP-100 will be evaluated in clinical trials as a therapy for relapse/refractory CLL patients, who have received at least two systemic therapies (NCT04704323). As nowadays many relapse/refractory CLL patients will have received ibrutinib as a prior therapy, we aimed to investigate in a large cohort of CLL patients the impact of this BTKi on CCR7 expression and functionality as well as on the therapeutic activity of CAP-100. Our data confirm that ibrutinib moderately down-regulates the very high expression of CCR7 in CLL cells but has no apparent effect on CCR7-induced chemotaxis. Moreover, CLL cells are perfectly targetable by CAP-100 which led to a complete inhibition of CCR7-mediated migration and induced strong target cell killing through antibody-dependent cell-mediated cytotoxicity, irrespective of previous or contemporary ibrutinib administration. Together, these results validate the therapeutic utility of CAP-100 as a next-line single-agent therapy for CLL patients who failed to ibrutinib and confirm that CAP-100 and ibrutinib have complementary non-overlapping mechanisms of action, potentially allowing for combination therapy., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
32. CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects.
- Author
-
Esparcia-Pinedo L, Martínez-Fleta P, Ropero N, Vera-Tomé P, Reyburn HT, Casasnovas JM, Rodríguez Frade JM, Valés-Gómez M, Vilches C, Martín-Gayo E, Muñoz-Calleja C, Sanchez-Madrid F, and Alfranca A
- Subjects
- Adult, Cells, Cultured, Convalescence, Female, Healthy Volunteers, Humans, Immunization, Secondary, Immunoglobulin A metabolism, Immunoglobulin G metabolism, Male, Middle Aged, Spike Glycoprotein, Coronavirus immunology, T-Cell Antigen Receptor Specificity, Vaccination, BNT162 Vaccine immunology, CD4-Positive T-Lymphocytes immunology, COVID-19 immunology, SARS-CoV-2 physiology
- Abstract
The immune response promoted by SARS-CoV-2 vaccination is relevant to develop novel vaccines and optimized prevention strategies. We analyzed the adaptive immunity in healthy donors (HD) and convalescent individuals (CD), before and after administering BNT162b2 vaccine. Our results revealed specific changes in CD4+ T cell reactivity profile in vaccinated HD and CD, with an increase in S1 and S2 positive individuals, proportionally higher for S2. On the contrary, NCAP reactivity observed in HD and CD patients was no longer detectable after vaccination. Despite the substantial antibody response in CD, MPro-derived peptides did not elicit CD4+ lymphocyte activation in our assay in either condition. HD presented an increment in anti-S and anti-RBD IgG after first dose vaccination, which increased after the second vaccination. Conversely, anti-S and anti-RBD IgG and IgA titers increased in already positive CD after first dose administration, remaining stable after second dose inoculation. Interestingly, we found a strong significant correlation between S1-induced CD4+ response and anti-S IgA pre-vaccination, which was lost after vaccine administration., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Esparcia-Pinedo, Martínez-Fleta, Ropero, Vera-Tomé, Reyburn, Casasnovas, Rodríguez Frade, Valés-Gómez, Vilches, Martín-Gayo, Muñoz-Calleja, Sanchez-Madrid and Alfranca.)
- Published
- 2022
- Full Text
- View/download PDF
33. A Differential Signature of Circulating miRNAs and Cytokines Between COVID-19 and Community-Acquired Pneumonia Uncovers Novel Physiopathological Mechanisms of COVID-19.
- Author
-
Martínez-Fleta P, Vera-Tomé P, Jiménez-Fernández M, Requena S, Roy-Vallejo E, Sanz-García A, Lozano-Prieto M, López-Sanz C, Vara A, Lancho-Sánchez Á, Martín-Gayo E, Muñoz-Calleja C, Alfranca A, González-Álvaro I, Galván-Román JM, Aspa J, de la Fuente H, and Sánchez-Madrid F
- Subjects
- Biomarkers blood, COVID-19 blood, Cohort Studies, Community-Acquired Infections blood, Community-Acquired Infections immunology, Female, Humans, Logistic Models, Male, Middle Aged, Pneumonia blood, COVID-19 immunology, Circulating MicroRNA blood, Cytokines blood, Pneumonia immunology
- Abstract
Coronavirus Disease 2019 (COVID-19) pneumonia is a life-threatening infectious disease, especially for elderly patients with multiple comorbidities. Despite enormous efforts to understand its underlying etiopathogenic mechanisms, most of them remain elusive. In this study, we compared differential plasma miRNAs and cytokines profiles between COVID-19 and other community-acquired pneumonias (CAP). A first screening and subsequent validation assays in an independent cohort of patients revealed a signature of 15 dysregulated miRNAs between COVID-19 and CAP patients. Additionally, multivariate analysis displayed a combination of 4 miRNAs (miR-106b-5p, miR-221-3p, miR-25-3p and miR-30a-5p) that significantly discriminated between both pathologies. Search for targets of these miRNAs, combined with plasma protein measurements, identified a differential cytokine signature between COVID-19 and CAP that included EGFR, CXCL12 and IL-10. Significant differences were also detected in plasma levels of CXCL12, IL-17, TIMP-2 and IL-21R between mild and severe COVID-19 patients. These findings provide new insights into the etiopathological mechanisms underlying COVID-19., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Martínez-Fleta, Vera-Tomé, Jiménez-Fernández, Requena, Roy-Vallejo, Sanz-García, Lozano-Prieto, López-Sanz, Vara, Lancho-Sánchez, Martín-Gayo, Muñoz-Calleja, Alfranca, González-Álvaro, Galván-Román, Aspa, de la Fuente and Sánchez-Madrid.)
- Published
- 2022
- Full Text
- View/download PDF
34. Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses.
- Author
-
Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, Juárez-Sánchez R, Ursa A, Vega-Piris L, Pascual-Salcedo D, de Vries A, Rispens T, and Muñoz-Calleja C
- Abstract
Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy. Objective: To assess in a single study the individual and treatment characteristics that influence the pharmacokinetics and pharmacodynamics of natalizumab in multiple sclerosis (MS) patients in the real-world practice. Methods: Prospective observational study to analyse the impact of body weight, height, body surface area, body mass index, gender, age, treatment duration, and dosage scheme on natalizumab concentrations and the occupancy of α4-integrin receptor (RO) by natalizumab. Results: Natalizumab concentrations ranged from 0.72 to 67 μg/ml, and RO from 26 to 100%. Body mass index inversely associated with natalizumab concentration (beta = -1.78; p ≤ 0.001), as it did body weight (beta = -0.34; p = 0.001), but not height, body surface area, age or gender Extended vs. standard dose scheme, but not treatment duration, was inversely associated with natalizumab concentration (beta = -7.92; p = 0.016). Similar to natalizumab concentration, body mass index (beta = -1.39; p = 0.001) and weight (beta = -0.31; p = 0.001) inversely impacted RO. Finally, there was a strong direct linear correlation between serum concentrations and RO until 9 μg/ml (rho = 0.71; p = 0.003). Nevertheless, most patients had higher concentrations of natalizumab resulting in the saturation of the integrin. Conclusions: Body mass index and dosing interval are the main variables found to influence the pharmacology of natalizumab. Plasma concentration of natalizumab and/or RO are wide variable among patients and should be routinely measured to personalize treatment and, therefore, avoid either over and underdosing., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Serra López-Matencio, Pérez García, Meca-Lallana, Juárez-Sánchez, Ursa, Vega-Piris, Pascual-Salcedo, de Vries, Rispens and Muñoz-Calleja.)
- Published
- 2021
- Full Text
- View/download PDF
35. Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients.
- Author
-
Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, Martín Ramírez A, Rodríguez-García SC, Arevalillo-Fernández N, Galván-Román JM, Fontán García-Rodrigo L, Vega-Piris L, Chicot Llano M, Arribas Méndez D, González de Marcos B, Hernando Santos J, Sánchez Azofra A, Ávalos Pérez-Urria E, Rodriguez-Cortes P, Esparcia L, Marcos-Jimenez A, Sánchez-Alonso S, Llorente I, Soriano J, Suárez Fernández C, García-Vicuña R, Ancochea J, Sanz J, Muñoz-Calleja C, de la Cámara R, Canabal Berlanga A, González-Álvaro I, and Cardeñoso L
- Subjects
- Aged, Biomarkers blood, COVID-19 mortality, COVID-19 virology, Critical Care, Female, Hospitalization, Humans, Interleukin-6 blood, Male, Middle Aged, Patient Acuity, Real-Time Polymerase Chain Reaction, Retrospective Studies, Risk Factors, Spain, Viremia virology, COVID-19 blood, RNA, Viral blood, SARS-CoV-2 genetics, Viremia blood
- Abstract
COVID-19 has overloaded national health services worldwide. Thus, early identification of patients at risk of poor outcomes is critical. Our objective was to analyse SARS-CoV-2 RNA detection in serum as a severity biomarker in COVID-19. Retrospective observational study including 193 patients admitted for COVID-19. Detection of SARS-CoV-2 RNA in serum (viremia) was performed with samples collected at 48-72 h of admission by two techniques from Roche and Thermo Fischer Scientific (TFS). Main outcome variables were mortality and need for ICU admission during hospitalization for COVID-19. Viremia was detected in 50-60% of patients depending on technique. The correlation of Ct in serum between both techniques was good (intraclass correlation coefficient: 0.612; p < 0.001). Patients with viremia were older (p = 0.006), had poorer baseline oxygenation (PaO
2 /FiO2 ; p < 0.001), more severe lymphopenia (p < 0.001) and higher LDH (p < 0.001), IL-6 (p = 0.021), C-reactive protein (CRP; p = 0.022) and procalcitonin (p = 0.002) serum levels. We defined "relevant viremia" when detection Ct was < 34 with Roche and < 31 for TFS. These thresholds had 95% sensitivity and 35% specificity. Relevant viremia predicted death during hospitalization (OR 9.2 [3.8-22.6] for Roche, OR 10.3 [3.6-29.3] for TFS; p < 0.001). Cox regression models, adjusted by age, sex and Charlson index, identified increased LDH serum levels and relevant viremia (HR = 9.87 [4.13-23.57] for TFS viremia and HR = 7.09 [3.3-14.82] for Roche viremia) as the best markers to predict mortality. Viremia assessment at admission is the most useful biomarker for predicting mortality in COVID-19 patients. Viremia is highly reproducible with two different techniques (TFS and Roche), has a good consistency with other severity biomarkers for COVID-19 and better predictive accuracy.- Published
- 2021
- Full Text
- View/download PDF
36. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
- Author
-
Cuesta-Mateos C, Brown JR, Terrón F, and Muñoz-Calleja C
- Subjects
- Animals, B-Lymphocytes metabolism, Biomarkers, Tumor, Chemotaxis genetics, Chemotaxis immunology, Gene Expression, Humans, Immune Tolerance, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Ligands, Lymph Nodes immunology, Molecular Targeted Therapy, Protein Binding, Receptors, CCR7 antagonists & inhibitors, Receptors, CCR7 genetics, Tumor Microenvironment, Disease Susceptibility, Leukemia, Lymphocytic, Chronic, B-Cell etiology, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Lymph Nodes metabolism, Receptors, CCR7 metabolism
- Abstract
The lymph node (LN) is an essential tissue for achieving effective immune responses but it is also critical in the pathogenesis of chronic lymphocytic leukemia (CLL). Within the multitude of signaling pathways aberrantly regulated in CLL the homeostatic axis composed by the chemokine receptor CCR7 and its ligands is the main driver for directing immune cells to home into the LN. In this literature review, we address the roles of CCR7 in the pathophysiology of CLL, and how this chemokine receptor is of critical importance to develop more rational and effective therapies for this malignancy., Competing Interests: CC-M is an employee of Catapult Therapeutics and of Immunological and Medical Products (IMMED S.L.), and a shareholder in this last company. FT declares that he is CEO and a shareholder in the same companies. CM-C is a consultant for IMMED S.L., who has a granted patent for the use of therapeutic antibodies targeting CCR7 in cancer and has received research funds from IMMED.S.L. and Catapult Therapeutics. She also holds shares in IMMED S.L. JB has served as a consultant for Abbvie, Acerta, Astra-Zeneca, Beigene, Catapult, Dynamo Therapeutics, Eli Lilly, Genentech/Roche, Gilead, Juno/Celgene/Bristol Myers Squibb, Kite, Loxo, MEI Pharma, Nextcea, Novartis, Octapharma, Pfizer, Pharmacyclics, Rigel, Sunesis, TG Therapeutics, Verastem; received honoraria from Janssen, received research funding from Gilead, Loxo, Sun, TG Therapeutics and Verastem; and served on data safety monitoring committees for Invectys., (Copyright © 2021 Cuesta-Mateos, Brown, Terrón and Muñoz-Calleja.)
- Published
- 2021
- Full Text
- View/download PDF
37. Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients.
- Author
-
Marcos-Jiménez A, Sánchez-Alonso S, Alcaraz-Serna A, Esparcia L, López-Sanz C, Sampedro-Núñez M, Mateu-Albero T, Sánchez-Cerrillo I, Martínez-Fleta P, Gabrie L, Del Campo Guerola L, Rodríguez-Frade JM, Casasnovas JM, Reyburn HT, Valés-Gómez M, López-Trascasa M, Martín-Gayo E, Calzada MJ, Castañeda S, de la Fuente H, González-Álvaro I, Sánchez-Madrid F, Muñoz-Calleja C, and Alfranca A
- Subjects
- Aged, COVID-19 immunology, Complement C3 analysis, Complement C4 analysis, Complement C5 analysis, Female, Humans, Immunoglobulin A blood, Immunoglobulin G blood, Immunoglobulin M blood, Lymphocyte Count, Lymphopenia immunology, Male, Middle Aged, Respiratory Distress Syndrome immunology, Respiratory Distress Syndrome pathology, B-Lymphocytes immunology, COVID-19 pathology, Immunoglobulins blood, Killer Cells, Natural immunology, SARS-CoV-2 immunology, T-Lymphocytes, Helper-Inducer immunology
- Abstract
SARS-CoV-2 infection causes an abrupt response by the host immune system, which is largely responsible for the outcome of COVID-19. We investigated whether the specific immune responses in the peripheral blood of 276 patients were associated with the severity and progression of COVID-19. At admission, dramatic lymphopenia of T, B, and NK cells is associated with severity. Conversely, the proportion of B cells, plasmablasts, circulating follicular helper T cells (cTfh) and CD56
- CD16+ NK-cells increased. Regarding humoral immunity, levels of IgM, IgA, and IgG were unaffected, but when degrees of severity were considered, IgG was lower in severe patients. Compared to healthy donors, complement C3 and C4 protein levels were higher in mild and moderate, but not in severe patients, while the activation peptide of C5 (C5a) increased from the admission in every patient, regardless of their severity. Moreover, total IgG, the IgG1 and IgG3 isotypes, and C4 decreased from day 0 to day 10 in patients who were hospitalized for more than two weeks, but not in patients who were discharged earlier. Our study provides important clues to understand the immune response observed in COVID-19 patients, associating severity with an imbalanced humoral response, and identifying new targets for therapeutic intervention., (© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)- Published
- 2021
- Full Text
- View/download PDF
38. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
- Author
-
Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, Alcaraz-Serna A, Mateu-Albero T, Rodríguez-Cortes P, Sánchez-Cerrillo I, Esparcia L, Martínez-Fleta P, López-Sanz C, Gabrie L, Del Campo Guerola L, Suárez-Fernández C, Ancochea J, Canabal A, Albert P, Rodríguez-Serrano DA, Aguilar JM, Del Arco C, de Los Santos I, García-Fraile L, de la Cámara R, Serra JM, Ramírez E, Alonso T, Landete P, Soriano JB, Martín-Gayo E, Fraile Torres A, Zurita Cruz ND, García-Vicuña R, Cardeñoso L, Sánchez-Madrid F, Alfranca A, Muñoz-Calleja C, and González-Álvaro I
- Subjects
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Antibodies, Monoclonal, Humanized administration & dosage, COVID-19 blood, COVID-19 mortality, Cytokine Release Syndrome blood, Cytokine Release Syndrome drug therapy, Cytokine Release Syndrome mortality, Interleukin-6 blood, SARS-CoV-2, COVID-19 Drug Treatment
- Abstract
Background: Patients with coronavirus disaese 2019 (COVID-19) can develop a cytokine release syndrome that eventually leads to acute respiratory distress syndrome requiring invasive mechanical ventilation (IMV). Because IL-6 is a relevant cytokine in acute respiratory distress syndrome, the blockade of its receptor with tocilizumab (TCZ) could reduce mortality and/or morbidity in severe COVID-19., Objective: We sought to determine whether baseline IL-6 serum levels can predict the need for IMV and the response to TCZ., Methods: A retrospective observational study was performed in hospitalized patients diagnosed with COVID-19. Clinical information and laboratory findings, including IL-6 levels, were collected approximately 3 and 9 days after admission to be matched with preadministration and postadministration of TCZ. Multivariable logistic and linear regressions and survival analysis were performed depending on outcomes: need for IMV, evolution of arterial oxygen tension/fraction of inspired oxygen ratio, or mortality., Results: One hundred forty-six patients were studied, predominantly males (66%); median age was 63 years. Forty-four patients (30%) required IMV, and 58 patients (40%) received treatment with TCZ. IL-6 levels greater than 30 pg/mL was the best predictor for IMV (odds ratio, 7.1; P < .001). Early administration of TCZ was associated with improvement in oxygenation (arterial oxygen tension/fraction of inspired oxygen ratio) in patients with high IL-6 (P = .048). Patients with high IL-6 not treated with TCZ showed high mortality (hazard ratio, 4.6; P = .003), as well as those with low IL-6 treated with TCZ (hazard ratio, 3.6; P = .016). No relevant serious adverse events were observed in TCZ-treated patients., Conclusions: Baseline IL-6 greater than 30 pg/mL predicts IMV requirement in patients with COVID-19 and contributes to establish an adequate indication for TCZ administration., (Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.
- Author
-
Cuesta-Mateos C, Juárez-Sánchez R, Mateu-Albero T, Loscertales J, Mol W, Terrón F, and Muñoz-Calleja C
- Subjects
- Animals, Antibodies, Monoclonal pharmacology, Antineoplastic Agents pharmacology, Humans, Immunoglobulin G pharmacology, Macaca fascicularis, Mice, Antibodies, Blocking pharmacology, Chemotaxis, Leukocyte drug effects, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Lymphatic Metastasis pathology, Receptors, CCR7 antagonists & inhibitors
- Abstract
Lymph node (LN) is a key tissue in the pathophysiology of mature blood cancers, especially for chronic lymphocytic leukemia (CLL). Within the multiple de-regulated pathways affecting CLL homeostasis, the CC-chemokine receptor 7 (CCR7) grants homing of CLL cells into the LN where protective environments foster tumor progression. To cover the lack of specific therapies targeting the CCR7-dependence of CLL to enter into the LN, and aiming to displace the disease from LN, we generated CAP-100, an antibody that specifically binds to hCCR7 and neutralizes its ligand-binding site and signaling. In various in vitro and i n vivo preclinical models CAP-100 strongly inhibited CCR7-induced migration, extravasation, homing, and survival in CLL samples. Moreover, it triggered potent tumor cell killing, mediated by host immune mechanisms, and was effective in xenograft models of high-risk disease. Additionally, CAP-100 showed a favorable toxicity profile on relevant hematopoietic subsets. Our results validated CAP-100 as a novel therapeutic tool to prevent the access of CLL cells, and other neoplasia with nodal-dependence, into the LN niches, thus hitting a central hub in the pathogenesis of cancer. The first-in-human clinical trial (NCT04704323), which will evaluate this novel therapeutic approach in CLL patients, is pending.
- Published
- 2021
- Full Text
- View/download PDF
40. COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes.
- Author
-
Sánchez-Cerrillo I, Landete P, Aldave B, Sánchez-Alonso S, Sánchez-Azofra A, Marcos-Jiménez A, Ávalos E, Alcaraz-Serna A, de Los Santos I, Mateu-Albero T, Esparcia L, López-Sanz C, Martínez-Fleta P, Gabrie L, Del Campo Guerola L, de la Fuente H, Calzada MJ, González-Álvaro I, Alfranca A, Sánchez-Madrid F, Muñoz-Calleja C, Soriano JB, Ancochea J, and Martín-Gayo E
- Subjects
- Adult, Aged, Aged, 80 and over, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes pathology, COVID-19 pathology, Dendritic Cells immunology, Dendritic Cells pathology, Female, Humans, Lung pathology, Male, Middle Aged, Monocytes classification, Monocytes pathology, Severity of Illness Index, Antigens, CD1 immunology, COVID-19 immunology, Cell Movement immunology, Glycoproteins immunology, Lung immunology, Monocytes immunology, Respiratory Distress Syndrome immunology, SARS-CoV-2 immunology
- Abstract
SARS-CoV-2 is responsible for the development of coronavirus disease 2019 (COVID-19) in infected individuals, who can either exhibit mild symptoms or progress toward a life-threatening acute respiratory distress syndrome (ARDS). Exacerbated inflammation and dysregulated immune responses involving T and myeloid cells occur in COVID-19 patients with severe clinical progression. However, the differential contribution of specific subsets of dendritic cells and monocytes to ARDS is still poorly understood. In addition, the role of CD8+ T cells present in the lung of COVID-19 patients and relevant for viral control has not been characterized. Here, we have studied the frequencies and activation profiles of dendritic cells and monocytes present in the blood and lung of COVID-19 patients with different clinical severity in comparison with healthy individuals. Furthermore, these subpopulations and their association with antiviral effector CD8+ T cell subsets were also characterized in lung infiltrates from critical COVID-19 patients. Our results indicate that inflammatory transitional and nonclassical monocytes and CD1c+ conventional dendritic cells preferentially migrate from blood to lungs in patients with severe COVID-19. Thus, this study increases the knowledge of specific myeloid subsets involved in the pathogenesis of COVID-19 disease and could be useful for the design of therapeutic strategies for fighting SARS-CoV-2 infection.
- Published
- 2020
- Full Text
- View/download PDF
41. CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
- Author
-
Cuesta-Mateos C, Fuentes P, Schrader A, Juárez-Sánchez R, Loscertales J, Mateu-Albero T, Vega-Piris L, Espartero-Santos M, Marcos-Jimenez A, Sánchez-López BA, Pérez-García Y, Jungherz D, Oberbeck S, Wahnschaffe L, Kreutzman A, Andersson EI, Mustjoki S, Faber E, Urzainqui A, Fresno M, Stamatakis K, Alfranca A, Terrón F, Herling M, Toribio ML, and Muñoz-Calleja C
- Abstract
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 is a molecule expressed in a wide range of malignancies and relevant in many tumor processes, the present study addressed the biologic role of this receptor in T-PLL. Furthermore, we elucidated the mechanisms of action mediated by an anti-CCR7 monoclonal antibody (mAb) and evaluated whether its anti-tumor activity would warrant development towards clinical applications in T-PLL. Our results demonstrate that CCR7 is a prognostic biomarker for overall survival in T-PLL patients and a functional receptor involved in the migration, invasion, and survival of leukemic cells. Targeting CCR7 with a mAb inhibited ligand-mediated signaling pathways and induced tumor cell killing in primary samples. In addition, directing antibodies against CCR7 was highly effective in T-cell leukemia xenograft models. Together, these findings make CCR7 an attractive molecule for novel mAb-based therapeutic applications in T-PLL, a disease where recent drug screen efforts and studies addressing new compounds have focused on chemotherapy or small molecules., Supplementary Information: Supplementary information accompanies this paper at 10.1186/s40364-020-00234-z., Competing Interests: Competing interestsCCM declares that he is an employee of Immunological and Medical Products (IMMED S.L.), Madrid, Spain. FT declares that he is CEO and a shareholder in the same company. CMC is consultant of IMMED S.L., has a granted patent for the use of therapeutic antibodies targeting CCR7 in cancer and has received research funds from IMMED.S.L. SM has received honoraria and research funding from BMS, Novartis and Pfizer (not related to this study). EF has received honoraria and research funding from Angelini, BMS, Novartis and Terumo BCT (not related to this study). The other authors declare that they have no potential competing interests., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
42. Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease.
- Author
-
Cuesta-Mateos C, Portero-Sainz I, García-Peydró M, Alcain J, Fuentes P, Juárez-Sánchez R, Pérez-García Y, Mateu-Albero T, Díaz-Fernández P, Vega-Piris L, Sánchez-López BA, Marcos-Jiménez A, Cardeñoso L, Gómez-García de Soria V, Toribio ML, and Muñoz-Calleja C
- Subjects
- Graft vs Leukemia Effect, Humans, T-Lymphocytes, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation adverse effects, Receptors, CCR7 drug effects
- Abstract
Graft-versus-host disease (GVHD) is the main complication after allogeneic hematopoietic stem cell transplantation. We previously unveiled a correlation between proportions of C-C motif chemokine receptor 7 (CCR7)
+ T cells in the apheresis and the risk of developing GVHD. We wanted to evaluate in vivo whether apheresis with low proportion of CCR7+ cells or treatment with an anti-human CCR7 monoclonal antibody (mAb) were suitable strategies to prevent or treat acute GVHD in preclinical xenogeneic models. Therapeutic anti-CCR7 mAb was the most effective strategy in both prophylactic and therapeutic settings where antibody drastically reduced in vivo lymphoid organ infiltration of donor CCR7+ T cells, extended lifespan and solved clinical signs. The antibody neutralized in vitro migration of naïve and central memory T cells toward CCR7 ligands and depleted target CCR7+ subsets through complement activation. Both mechanisms of action spared CCR7- subsets, including effector memory and effector memory CD45RA+ T cells which may mediate graft versus leukemia effect and immunity against infections. Accordingly, the numbers of donor CCR7+ T cells in the apheresis were not associated to cytomegalovirus reactivation or the recurrence of the underlying disease. These findings provide a promising new strategy to prevent and treat acute GVHD, a condition where new specific, safety and effective treatment is needed.- Published
- 2020
- Full Text
- View/download PDF
43. Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center.
- Author
-
López-Pereira P, Sola Aparicio E, Vicuña Andrés I, Cámara Montejano C, Muñoz Calleja C, Alegre Amor A, and Aguado Bueno B
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Transplantation, Autologous, Transplantation, Homologous, Blood Component Removal methods, Hematopoietic Stem Cell Mobilization methods, Hematopoietic Stem Cell Transplantation methods
- Abstract
Introduction: COBE SPECTRA [COBE] (Terumo, BCT Lakewood CO) apheresis system has been the most used device for hematopoietic progenitor cells (HPC) collection. Recently, it has been replaced by the SPECTRA OPTIA [OPTIA] (Terumo, BCT Lakewood CO) apheresis system. The aim of our study is to compare both methods for HPC collection., Material and Methods: We retrospectively compared 302 HPC collection apheresis procedures (115 allogeneic donors and 187 autologous). The study cohort was divided according to the apheresis system used to analyze the differences between COBE and OPTIA, specifically efficacy of apheresis procedure and product characteristics., Results: OPTIA collections result in a higher CD34
+ collection efficiency in both groups (autologous 45.3% vs 41%, P < .006; allogeneic 54.9% vs 45%, P < .0001). The total of CD34+ cells ×106 /kg recipient collected in the product were comparable in both groups (autologous 2.9 in OPTIA group vs 2.8 in COBE group, P = .344; allogeneic 6.2 in OPTIA group vs 5.8 in COBE group, P = .186). The percentage of platelet loss in autologous donors was significantly lower (35.7% vs 40.8%, P < .01). Regarding quality of the product, we observed a significantly lower hematocrit in products collected with OPTIA in both groups (1.8% vs 4%, P < .0001) as well as significantly lower amount of leukocytes (median 153.4 vs 237.2 × 109 /L in autologous, P < .0001; 239.5 vs 340.2 × 109 /L in allogeneic P < .0001)., Conclusion: Both apheresis systems are comparable in collection of hematopoietic progenitor cells, with significantly higher collection efficiency with the OPTIA system. Collection products obtained with OPTIA contain significantly lower hematocrit and leukocytes., (© 2020 Wiley Periodicals LLC.)- Published
- 2020
- Full Text
- View/download PDF
44. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease.
- Author
-
Kim D, Park G, Huuhtanen J, Lundgren S, Khajuria RK, Hurtado AM, Muñoz-Calleja C, Cardeñoso L, Gómez-García de Soria V, Chen-Liang TH, Eldfors S, Ellonen P, Hannula S, Kankainen M, Bruck O, Kreutzman A, Salmenniemi U, Lönnberg T, Jerez A, Itälä-Remes M, Myllymäki M, Keränen MAI, and Mustjoki S
- Subjects
- Blotting, Western, Cell Proliferation genetics, Cell Proliferation physiology, HEK293 Cells, Humans, Immunity, Cellular genetics, Immunity, Cellular physiology, Immunoprecipitation, Mutation genetics, Protein Binding genetics, Protein Binding physiology, Graft vs Host Disease genetics, T-Lymphocytes metabolism, TOR Serine-Threonine Kinases genetics
- Abstract
Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4
+ T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2 mutations. In the screening cohort (n = 134), we detect the mTOR P2229R kinase domain mutation in two additional cGvHD patients, but not in healthy or HSCT patients without cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance measurements support increased cytotoxicity of mutated CD4+ T cells. High throughput drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may contribute to aberrant T cell proliferations and persistent immune activation in cGvHD, thereby paving the way for targeted therapies.- Published
- 2020
- Full Text
- View/download PDF
45. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
- Author
-
Domínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cibrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, and Zapata JM
- Subjects
- Animals, Antineoplastic Agents, Immunological chemistry, Antineoplastic Agents, Immunological therapeutic use, Cell Line, Tumor, Female, Humans, Immunoconjugates chemistry, Immunoconjugates therapeutic use, Mice, Mice, Nude, Neoplasms immunology, Polyketides chemistry, Polyketides therapeutic use, Pyrones chemistry, Pyrones therapeutic use, Antineoplastic Agents, Immunological pharmacology, CD13 Antigens immunology, Immunoconjugates pharmacology, Neoplasms drug therapy, Polyketides pharmacology, Pyrones pharmacology
- Abstract
Background: In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a differential pattern of expression in a variety of tumors and cell lines and it is internalized upon engagement with a suitable monoclonal antibody. PM050489 is a marine cytotoxic compound tightly binding tubulin and impairing microtubule dynamics which is currently undergoing clinical trials for solid tumors., Methods: Anti-CD13 monoclonal antibody (mAb) TEA1/8 has been used to prepare a novel ADC, MI130110, by conjugation to the marine compound PM050489. In vitro and in vivo experiments have been carried out to demonstrate the activity and specificity of MI130110., Results: CD13 is readily internalized upon TEA1/8 mAb binding, and the conjugation with PM050489 did not have any effect on the binding or the internalization of the antibody. MI130110 showed remarkable activity and selectivity in vitro on CD13-expressing tumor cells causing the same effects than those described for PM050489, including cell cycle arrest at G2, mitosis with disarrayed and often multipolar spindles consistent with an arrest at metaphase, and induction of cell death. In contrast, none of these toxic effects were observed in CD13-null cell lines incubated with MI130110. Furthermore, in vivo studies showed that MI130110 exhibited excellent antitumor activity in a CD13-positive fibrosarcoma xenograft murine model, with total remissions in a significant number of the treated animals. Mitotic catastrophes, typical of the payload mechanism of action, were also observed in the tumor cells isolated from mice treated with MI130110. In contrast, MI130110 failed to show any activity in a xenograft mouse model of myeloma cells not expressing CD13, thereby corroborating the selectivity of the ADC to its target and its stability in circulation., Conclusion: Our results show that MI130110 ADC combines the antitumor potential of the PM050489 payload with the selectivity of the TEA1/8 monoclonal anti-CD13 antibody and confirm the correct intracellular processing of the ADC. These results demonstrate the suitability of CD13 as a novel ADC target and the effectiveness of MI130110 as a promising antitumor therapeutic agent.
- Published
- 2020
- Full Text
- View/download PDF
46. Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
- Author
-
Colom-Fernández B, Kreutzman A, Marcos-Jiménez A, García-Gutiérrez V, Cuesta-Mateos C, Portero-Sainz I, Pérez-García Y, Casado LF, Sánchez-Guijo F, Martínez-López J, Ayala RM, Boqué C, Xicoy B, Montero I, Soto C, Paz R, Silva G, Vega-Piris L, Steegmann JL, and Muñoz-Calleja C
- Abstract
Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. Since the underlying mechanisms are unknown and SRC family kinases are involved in many cell motility processes, we hypothesized that the movement and migration of lymphocytes is modulated by dasatinib. Patients, Materials and Methods: Peripheral blood samples from CML patients treated with second-line dasatinib were collected before and 2 h after the first dasatinib intake, and follow-up samples from the same patients 3 and 6 months after the start of therapy. The migratory capacity and phenotype of lymphocytes and differential blood counts before and after drug intake were compared for all study time-points. Results: We report here for the first time that dasatinib intake is associated with inhibition of peripheral blood T-cell migration toward the homeostatic chemokines CCL19 and CCL21, which control the trafficking toward secondary lymphoid organs, mainly the lymph nodes. Accordingly, the proportion of lymphocytes in blood expressing CCR7, the chemokine receptor for both CCL19 and CCL21, decreased after the intake including both naïve CD45RA+ and central memory CD45RO+ T-cells. Similarly, naïve B-cells diminished with dasatinib. Finally, such changes in the migratory patterns did not occur in those patients whose lymphocyte counts remained unchanged after taking the drug. Discussion: We, therefore, conclude that lymphocytosis induced by dasatinib reflects a pronounced redistribution of naïve and memory populations of all lymphocyte subsets including CD4+ and CD8+ T-cells and B-cells., (Copyright © 2019 Colom-Fernández, Kreutzman, Marcos-Jiménez, García-Gutiérrez, Cuesta-Mateos, Portero-Sainz, Pérez-García, Casado, Sánchez-Guijo, Martínez-López, Ayala, Boqué, Xicoy, Montero, Soto, Paz, Silva, Vega-Piris, Steegmann and Muñoz-Calleja.)
- Published
- 2019
- Full Text
- View/download PDF
47. A Neutrophil Timer Coordinates Immune Defense and Vascular Protection.
- Author
-
Adrover JM, Del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga-Encabo H, Silvestre-Roig C, Rossaint J, Cossío I, Lechuga-Vieco AV, García-Prieto J, Gómez-Parrizas M, Quintana JA, Ballesteros I, Martin-Salamanca S, Aroca-Crevillen A, Chong SZ, Evrard M, Balabanian K, López J, Bidzhekov K, Bachelerie F, Abad-Santos F, Muñoz-Calleja C, Zarbock A, Soehnlein O, Weber C, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, and Hidalgo A
- Published
- 2019
- Full Text
- View/download PDF
48. Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.
- Author
-
Cañamares I, Merino L, López J, Llorente I, García-Vadillo A, Ramirez E, López-Bote JP, Benedí J, Muñoz-Calleja C, Álvaro-Gracia JM, Castañeda S, and González-Álvaro I
- Subjects
- Antirheumatic Agents administration & dosage, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Monitoring methods, Female, Humans, Male, Middle Aged, Patient Acuity, Retrospective Studies, Spain epidemiology, Tertiary Care Centers statistics & numerical data, Treatment Outcome, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology, Rituximab administration & dosage
- Abstract
Background/objective: There is evidence supporting that there are no relevant clinical differences between dosing rituximab 1000 mg or 2000 mg per cycle in rheumatoid arthritis (RA) patients in clinical trials, and low-dose cycles seem to have a better safety profile. Our objective was to describe the pattern of use of rituximab in real-life practice conditions., Methods: Rituximab for RA in clinical practice (RITAR) study is a retrospective cohort study from 2005 to 2015. Eligibility criteria were RA adults treated with rituximab for active articular disease. Response duration was the main outcome defined as months elapsed from the date of rituximab first infusion to the date of flare. A multivariable analysis was performed to determine the variables associated with response duration., Results: A total of 114 patients and 409 cycles were described, 93.0% seropositive and 80.7% women. Rituximab was mainly used as second-line biological therapy. On demand retreatment was used in 94.6% of cases versus fixed 6 months retreatment in 5.4%. Median response duration to on demand rituximab cycles was 10 months (interquartile range, 7-13). Multivariable analysis showed that age older than 65 years, number of rituximab cycles, seropositivity, and first- or second-line therapy were associated with longer response duration. The dose administered at each cycle was not significantly associated with response duration., Conclusions: Our experience suggests that 1000 mg rituximab single infusion on demand is a reasonable schedule for long-term treatment of those patients with good response after the first cycles, especially in seropositive patients and when it is applied as a first- or second-line biological therapy.
- Published
- 2019
- Full Text
- View/download PDF
49. Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment.
- Author
-
López J, Merino L, Piris L, Herrera FS, Llorente I, Humbría A, Ortiz AM, Velasco T, García-Vicuña R, Castañeda S, González Álvaro I, and Muñoz-Calleja C
- Subjects
- Antibodies, Monoclonal, Murine-Derived, B-Lymphocytes, Humans, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid immunology, Rituximab therapeutic use
- Abstract
Objectives: Reconstitution of B-cells after their therapeutic depletion with rituximab mimics the ontogeny of the B-cell linage in patients with rheumatoid arthritis. However, little is known about the effects of multiple cycles of treatment on the repletion kinetics and their long-lasting effects on the B-cell compartment. We therefore compared the recovery capacity of the B cell subpopulations between patients who experienced their first cycle of rituximab and those who experienced successive cycles., Methods: The distribution of the different B-cell subsets was characterised by multiparametric flow cytometry in the peripheral blood of 29 patients in the first rituximab course (naïve cycles) and 40 patients in successive cycles. Samples were obtained at baseline and at 3, 6, and 8 months of each cycle., Results: The baseline percentage of B-cell subsets was similar among successive cycles. Therefore, successive cycles were grouped for comparison with naïve cycles. Patients in naïve cycles had higher percentages at baseline of both total and memory B-cells. However, the recovery of the different B-cell subsets was similar between naïve and successive cycles. In naïve patients the percentage of transitional B-cells significantly correlated with disease activity at baseline., Conclusions: Rituximab induces a long-term reshape of the B-cell compartment while multiple cycles of rituximab do not induce cumulative effects on B-cell subpopulations. Transitional B-cells seem to be associated with higher disease activity, although further studies are needed to determine if they can be used as a biomarker to predict the need for rituximab retreatment.
- Published
- 2019
50. Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.
- Author
-
Villarrubia N, Rodríguez-Martín E, Alari-Pahissa E, Aragón L, Castillo-Triviño T, Eixarch H, Ferrer JM, Martínez-Rodríguez JE, Massot M, Pinto-Medel MJ, Prada Á, Rodríguez-Acevedo B, Urbaneja P, Gascón-Gimenez F, Herrera G, Hernández-Clares R, Salgado MG, Oterino A, San Segundo D, Cuello JP, Gil-Herrera J, Cámara C, Gómez-Gutiérrez M, Martínez-Hernández E, Meca-Lallana V, Moga E, Muñoz-Calleja C, Querol L, Presas-Rodríguez S, Teniente-Serra A, Vlagea A, Muriel A, Roldán E, and Villar LM
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Multiple Sclerosis blood, Flow Cytometry, Interferon-beta therapeutic use, Multiple Sclerosis drug therapy
- Abstract
Background and Objectives: Percentages of blood CD19+CD5+ B cells and CD8+perforin+ T lymphocytes can predict response to Interferon (IFN)-beta treatment in relapsing-remitting multiple sclerosis (RRMS) patients. We aimed to standardize their detection in a multicenter study, prior to their implementation in clinical practice., Methods: Fourteen hospitals participated in the study. A reference centre was established for comparison studies. Peripheral blood cells of 105 untreated RRMS patients were studied. Every sample was analyzed in duplicate in the participating centre and in the reference one by flow cytometry. When needed, participating centres corrected fluorescence compensations and negative cut-off position following reference centre suggestions. Concordance between results obtained by participating centres and by reference one was evaluated by intraclass correlation coefficients (ICC) and Spearman correlation test. Centre performance was measured by using z-scores values., Results: After results review and corrective actions implementation, overall ICC was 0.86 (CI: 0.81-0.91) for CD19+CD5+ B cell and 0.89 (CI: 0.85-0.93) for CD8+ perforin+ T cell quantification; Spearman r was 0.92 (0.89-0.95; p <0.0001) and 0.92 (0.88-0.95; p <0.0001) respectively. All centres obtained z-scores≤0.5 for both biomarkers., Conclusion: Homogenous percentages of CD19+CD5+ B cells and CD8 perforin+ T lymphocytes can be obtained if suitable compensation values and negative cut-off are pre-established., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.